First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety and efficacy as well as improved workflow and short learning curve Now with two pulsed field…
Tag: AF
New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias
Data from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI) Preservation of raw unipolar signal using BioSig’s PURE EP™ platform guidance enabled real-time tissue-specific feedback when conducting ablation Cleveland, OH and Westport, […]
egnite Announces Portfolio Expansion to Reduce Stroke Risk in Atrial Fibrillation Patients
Expansion leverages a custom module to help health systems identify patients eligible for lifesaving therapy ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading digital health company for cardiovascular care, announces the expansion of its portfolio with the integration of a custom […]
Brainomix Technology Integrated into New UK Atrial Fibrillation Study
The study will assess the role of Huawei’s wearable technology to detect atrial fibrillation in post-stroke patients OXFORD, England, Feb. 22, 2023 /PRNewswire/ — Brainomix has announced its involvement in a new study sponsored by the University of Liverpool focused on post-stroke atrial fibrillation (AF). […]
New AF and Congenital Heart Disease Data on Vektor Medical’s vMap® Presented at the 15th Asia Pacific Heart Rhythm Society Scientific Session
SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced it presented new data on its vMap® technology that demonstrated potential utility in patients with adult congenital heart disease […]
egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation
Company to focus on improving the quality of care for all cardiovascular patients in the U.S. ALISO VIEJO, Calif.–(BUSINESS WIRE)–On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, […]
Adagio Medical Reports 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Presents Recent Developments of Pulsed Field Cryoablation Technology
LAGUNA HILLS, Calif., Aug. 3, 2021 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF […]
Adagio Medical Announces First-In-Human Use and Initiation of Multi-Center Study of Ultra-Low Temperature Cryoablation for Treatment of Recurrent Ventricular Tachycardia, Opening New Possibilities for High-Risk Patients
LAGUNA HILLS, Calif., July 6, 2021 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping […]
Acesion Pharma Strengthens Clinical Team With Key Appointments
Appoints experienced Chief Medical Officer and Director Clinical Operations COPENHAGEN, Denmark, May 5, 2020 /PRNewswire/ — Acesion Pharma, a Danish pharmaceutical company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, today announced that it has recruited Anders Gaarsdal Holst […]
Adagio Medical Announces US FDA Investigational Device Exemption Approval With Conditions To Conduct A Clinical Study For Treatment Of Persistent Atrial Fibrillation Using The Ultra-Low Temperature Cryoablation System
LAGUNA HILLS, Calif., Aug. 19, 2019 /PRNewswire/ — Adagio Medical, Inc. (Adagio), the developer of iCLAS™, the company’s ultra-low temperature intelligent continuous lesion ablation system, announced that it has received an Investigational Device Exemption approval with conditions from the US Food and Drug Administration (FDA) […]